Carlyle Group L.P. Stock News

Carlyle Group expects to take more of its portfolio companies public this year and will not shy away from large leveraged buyouts, betting on a rebound in U.S. dealmaking this year, its heads of private equity told Reuters.

CONSHOHOCKEN, Pa. , Feb. 24, 2025 /PRNewswire/ -- NSM Insurance Group ("NSM"), a global specialty insurance provider, announced today it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital ("New Mountain"), a leading growth-oriented investment firm with over $55 billion in assets under management.

Surging revenue from asset management businesses appeared to lift the spirits of private equity's Big Four firms. The middle market drove the increase in the monetization of portfolio company investments in 2024.

NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by bluebird bio, Inc. (NASDAQ: BLUE) and its board of directors concerning the proposed acquisition of the company by Carlyle (NASDAQ: CG) and SK Capital Partners, LP. Stockholders will receive $3.00 and a contingent value right of $6.84 for each share of bluebird bio stock that they hold.

PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly exper...

Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ending its tumultuous journey in the public markets as it struggled with a severe cash crunch.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen,...

Record revenues from management fees and a brighter outlook for M&A in the year ahead helped private equity's Big Four close 2024 on a high note. The average net positivity score for the four largest listed alternative asset managers - Apollo Global Management, Blackstone, The Carlyle, and KKR - rose to its highest level in several years, according to an S&P Global Market Intelligence analysis.